David Shaw’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $89.3M | Buy |
1,048,103
+341,472
| +48% | +$24.5M | 0.04% | 490 |
|
|
2026
Q1 | $46.6M | Buy |
706,631
+587,410
| +493% | +$37.3M | 0.03% | 687 |
|
|
2025
Q4 | $7.58M | Buy |
119,221
+105,618
| +776% | +$6.57M | ﹤0.01% | 1988 |
|
|
2025
Q3 | $748K | Sell |
13,603
-5,481
| -29% | -$226K | ﹤0.01% | 3638 |
|
|
2025
Q2 | $631K | Buy |
19,084
+5,782
| +43% | +$201K | ﹤0.01% | 3529 |
|
|
2025
Q1 | $535K | Buy |
+13,302
| New | +$611K | ﹤0.01% | 3469 |
|
|
2024
Q4 | – | Sell |
-11,790
| Closed | -$612K | – | 4480 |
|
|
2024
Q3 | $623K | Buy |
+11,790
| New | +$657K | ﹤0.01% | 3579 |
|
|
2024
Q2 | – | Sell |
-36,554
| Closed | -$2.21M | – | 4544 |
|
|
2024
Q1 | $2.56M | Buy |
+36,554
| New | +$2.83M | ﹤0.01% | 2436 |
|
|
2022
Q4 | – | Sell |
-41,935
| Closed | -$2.03M | – | 4904 |
|
|
2022
Q3 | $2.03M | Buy |
+41,935
| New | +$2.02M | ﹤0.01% | 2992 |
|
|
2022
Q1 | – | Sell |
-106,281
| Closed | -$4.84M | – | 5603 |
|
|
2021
Q4 | $4.84M | Buy |
+106,281
| New | +$4.1M | ﹤0.01% | 2412 |
|
|
2021
Q2 | – | Sell |
-92,247
| Closed | -$2.15M | – | 4788 |
|
|
2021
Q1 | $2.15M | Buy |
92,247
+41,329
| +81% | +$882K | ﹤0.01% | 2528 |
|
|
2020
Q4 | $1.06M | Buy |
+50,918
| New | +$931K | ﹤0.01% | 2984 |
|
|
2020
Q3 | – | Sell |
-49,028
| Closed | -$1.16M | – | 3899 |
|
|
2020
Q2 | $1.16M | Buy |
49,028
+15,803
| +48% | +$296K | ﹤0.01% | 2819 |
|
|
2020
Q1 | $392K | Sell |
33,225
-239,325
| -88% | -$3.05M | ﹤0.01% | 3327 |
|
|
2019
Q4 | $2.89M | Buy |
272,550
+232,113
| +574% | +$2.38M | ﹤0.01% | 2178 |
|
|
2019
Q3 | $460K | Sell |
40,437
-38,557
| -49% | -$484K | ﹤0.01% | 3250 |
|
|
2019
Q2 | $889K | Sell |
78,994
-128,245
| -62% | -$1.24M | ﹤0.01% | 2745 |
|
|
2019
Q1 | $1.68M | Buy |
207,239
+20,156
| +11% | +$148K | ﹤0.01% | 2291 |
|
|
2018
Q4 | $1.18M | Buy |
187,083
+61,344
| +49% | +$450K | ﹤0.01% | 2546 |
|
|
2018
Q3 | $1.24M | Buy |
125,739
+6,988
| +6% | +$56.1K | ﹤0.01% | 2540 |
|
|
2018
Q2 | $986K | Buy |
118,751
+15,393
| +15% | +$128K | ﹤0.01% | 2713 |
|
|
2018
Q1 | $745K | Buy |
103,358
+11,132
| +12% | +$95.4K | ﹤0.01% | 2683 |
|
|
2017
Q4 | $752K | Sell |
92,226
-53,440
| -37% | -$607K | ﹤0.01% | 2740 |
|
|
2017
Q3 | $2.11M | Sell |
145,666
-58,379
| -29% | -$797K | ﹤0.01% | 1982 |
|
|
2017
Q2 | $2.47M | Buy |
204,045
+36,943
| +22% | +$513K | ﹤0.01% | 1839 |
|
|
2017
Q1 | $2.15M | Sell |
167,102
-86,418
| -34% | -$1.01M | ﹤0.01% | 1795 |
|
|
2016
Q4 | $3.08M | Sell |
253,520
-57,439
| -18% | -$610K | 0.01% | 1688 |
|
|
2016
Q3 | $2.85M | Buy |
310,959
+6,279
| +2% | +$65.6K | 0.01% | 1662 |
|
|
2016
Q2 | $2.89M | Sell |
304,680
-1,746
| -0.6% | -$14.3K | 0.01% | 1658 |
|
|
2016
Q1 | $2.16M | Sell |
306,426
-78,114
| -20% | -$571K | ﹤0.01% | 1830 |
|
|
2015
Q4 | $4.02M | Sell |
384,540
-91,052
| -19% | -$893K | 0.01% | 1577 |
|
|
2015
Q3 | $3.18M | Sell |
475,592
-118,824
| -20% | -$811K | ﹤0.01% | 1734 |
|
|
2015
Q2 | $4M | Sell |
594,416
-137,029
| -19% | -$899K | 0.01% | 1638 |
|
|
2015
Q1 | $4.96M | Sell |
731,445
-201,882
| -22% | -$1.51M | 0.01% | 1389 |
|
|
2014
Q4 | $7.48M | Sell |
933,327
-8,384
| -0.9% | -$36K | 0.01% | 1290 |
|
|
2014
Q3 | $3.31M | Buy |
941,711
+104,362
| +12% | +$438K | ﹤0.01% | 1839 |
|
|
2014
Q2 | $4M | Buy |
+837,349
| New | +$5.11M | 0.01% | 1775 |
|
|
2014
Q1 | – | Sell |
-15,237
| Closed | -$99K | – | 4340 |
|
|
2013
Q4 | $99K | Sell |
15,237
-48,944
| -76% | -$322K | ﹤0.01% | 4369 |
|
|
2013
Q3 | $487K | Buy |
+64,181
| New | +$688K | ﹤0.01% | 3592 |
|
Other funds holding CYTK
ACA
David Shaw's CYTK Position: Q2 2026 in Review
David Shaw increased its Cytokinetics (CYTK) stake by 48% in Q2 2026, buying an estimated $24.5M and bringing the position to 1,048,103 shares worth $89.3M. The position accounts for 0.04% of the portfolio, ranked #490.
David Shaw first reported a position in CYTK in Q3 2013 and has held it in 39 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- David Shaw held 1,048,103 shares of Cytokinetics worth $89.3M as of Q2 2026.
- David Shaw bought 341,472 Cytokinetics shares in Q2 2026, an estimated $24.5M.
- Cytokinetics made up 0.04% of David Shaw's portfolio in Q2 2026, its #490 holding.
- David Shaw first reported a position in Cytokinetics in Q3 2013 and has held it in 39 quarters since.
- 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.